AR090510A1 - Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo - Google Patents

Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo

Info

Publication number
AR090510A1
AR090510A1 ARP130100989A AR090510A1 AR 090510 A1 AR090510 A1 AR 090510A1 AR P130100989 A ARP130100989 A AR P130100989A AR 090510 A1 AR090510 A1 AR 090510A1
Authority
AR
Argentina
Prior art keywords
antibodies
hcmv
detection
methods
same
Prior art date
Application number
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR090510A1 publication Critical patent/AR090510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un anticuerpo anti-idiotípico aislado, caracterizado porque específicamente enlaza un anticuerpo anti-HCMV que comprende la secuencia de cadena pesada de SEC ID Nº 1 y la secuencia de cadena ligera de SEC ID Nº 2 o un anticuerpo anti-HCMV que comprende la secuencia de cadena pesada de SEC ID Nº 3 y la secuencia de cadena ligera de SEC ID Nº 4.
ARP130100989 2012-03-28 2013-03-26 Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo AR090510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261616914P 2012-03-28 2012-03-28

Publications (1)

Publication Number Publication Date
AR090510A1 true AR090510A1 (es) 2014-11-19

Family

ID=48087712

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100989 AR090510A1 (es) 2012-03-28 2013-03-26 Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo

Country Status (12)

Country Link
US (2) US9139659B2 (es)
EP (1) EP2831119A1 (es)
JP (1) JP2015518471A (es)
KR (1) KR20140138971A (es)
CN (1) CN104334583A (es)
AR (1) AR090510A1 (es)
BR (1) BR112014024023A2 (es)
CA (1) CA2868161A1 (es)
HK (1) HK1206759A1 (es)
MX (1) MX2014011646A (es)
RU (1) RU2014143251A (es)
WO (1) WO2013148373A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060371A1 (en) * 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
RU2768404C2 (ru) 2016-12-23 2022-03-24 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
MX2019008348A (es) 2017-01-18 2019-10-21 Genentech Inc Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
JP7366755B2 (ja) * 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ 抗ダブルコルチン様キナーゼ１抗体および使用方法
CN111818939B (zh) 2017-12-04 2024-09-17 俄克拉荷马大学董事会 抗dclk1抗体和嵌合抗原受体及其组合物和使用方法
EP3952999A4 (en) 2019-04-09 2023-01-25 Abcuro, Inc. ANTIBODIES WITH DEPLETIVE ACTION ON THE KLRG1 RECEPTOR (KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1)
CN112899235B (zh) * 2019-12-03 2024-06-21 夏尔巴生物技术(苏州)有限公司 一种细胞培养液的收获方法
WO2022251311A1 (en) * 2021-05-25 2022-12-01 Seagen Inc. Methods of quantifying anti-cd40 antibodies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) * 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
FR2046920B1 (es) * 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4536479A (en) * 1983-03-22 1985-08-20 E. I. Du Pont De Nemours And Company Use of anti-idiotype antibodies in immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6020208A (en) 1994-05-27 2000-02-01 Baylor College Of Medicine Systems for surface-enhanced affinity capture for desorption and detection of analytes
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US20020139751A1 (en) 2001-02-20 2002-10-03 Sheng Zhang Microchip electrospray device and column with affinity adsorbents and use of the same
US20080268459A1 (en) * 2003-08-14 2008-10-30 Wyeth Ludwig Institute For Cancer Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US8153129B2 (en) 2006-12-15 2012-04-10 Ribovax Biotechnologies S.A. Antibodies against human cytimegalovirus (HCMV)
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
CA3022196A1 (en) * 2008-07-16 2010-01-21 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
EP2516463B1 (en) * 2009-12-23 2016-06-15 4-Antibody AG Binding members for human cytomegalovirus
US20120082666A1 (en) * 2010-09-29 2012-04-05 Xiaocheng Chen Antibody compositions and methods of use
EP2793941A1 (en) * 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies

Also Published As

Publication number Publication date
HK1206759A1 (en) 2016-01-15
BR112014024023A2 (pt) 2017-07-18
US9139659B2 (en) 2015-09-22
KR20140138971A (ko) 2014-12-04
CA2868161A1 (en) 2013-10-03
EP2831119A1 (en) 2015-02-04
JP2015518471A (ja) 2015-07-02
US20160002355A1 (en) 2016-01-07
WO2013148373A1 (en) 2013-10-03
WO2013148373A8 (en) 2014-09-25
CN104334583A (zh) 2015-02-04
US20130266973A1 (en) 2013-10-10
MX2014011646A (es) 2015-02-24
RU2014143251A (ru) 2016-05-20

Similar Documents

Publication Publication Date Title
AR090510A1 (es) Anticuerpos anti-idiotipicos que se unen a anticuerpos contra el citomegalovirus humano (ab anti-hcmv), metodos de deteccion de los mismos y kit de inmunoensayo
CY1122907T1 (el) Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1124428T1 (el) Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1
CO2019005842A2 (es) Anticuerpos anti-pd-l1 radiomarcados para imágenes de inmuno-pet
ECSP13012440A (es) Anticuerpos anti-fap y métodos de uso
TR201900160T4 (tr) Bir anti-ilaç antikoru varlığının veya miktarının saptanmasına yönelik analizler.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CO6720984A2 (es) Anticuerpos anti-mesotelina e inmunoconjugados
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
PE20121616A1 (es) Anticuerpos anti-her3
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS